van Dorst, Pim W. M. http://orcid.org/0000-0001-8401-0932
van der Pol, Simon
Olliaro, Piero
Dittrich, Sabine
Nkeramahame, Juvenal
Postma, Maarten J.
Boersma, Cornelis
van Asselt, Antoinette D. I.
Funding for this research was provided by:
FIND
Article History
Accepted: 5 May 2024
First Online: 25 May 2024
Declarations
:
: Pim W.M. van Dorst, Piero Olliaro, Sabine Dittrich, Juvenal Nkeramahame, Simon van der Pol and Antoinette D.I. van Asselt have no reported conflicts of interest. Prof. Maarten Postma holds of stocks of Pharmacoeconomics Advice Groningen (Netherlands) and Health-Ecore (Zeist, Netherlands). Prof. Cornelis Boersma holds stocks of Health-Ecore (Zeist, Netherlands). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the article have been disclosed.
: The AMR Diagnostics Use Accelerator trial was registered with the US National Library of Medicine Clinical Trials database (identifier: NCT04081051). The overarching protocol was reviewed and approved by the Human Research Ethics Committee of the University of Oxford, United Kingdom. In addition, country-specific protocols were reviewed and approved by relevant regulatory authorities and national and/or institutional ethics committees in all participating countries.
: Written informed consent was provided by all participating adults and official caregivers of participating children.
: The study participants and official caregivers of participating children consented to their data being used for publication.
: The data that support the findings of this study were provided by FIND, who received funding from the UK government for this study. Restrictions apply to the availability of these data and so are not publicly available. Data are available from the authors upon reasonable request and with permission of FIND.
: The R model is available from the authors upon reasonable request and with permission of FIND.